Next Article in Journal
Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature
Previous Article in Journal
Differences in Anxiety Levels of Various Murine Models in Relation to the Gut Microbiota Composition
Open AccessReview

The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

1
Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
2
Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan
*
Author to whom correspondence should be addressed.
Biomedicines 2018, 6(4), 114; https://doi.org/10.3390/biomedicines6040114
Received: 10 November 2018 / Revised: 29 November 2018 / Accepted: 4 December 2018 / Published: 7 December 2018
The programmed death-ligand 1(PD-L1)/PD-1 pathway is an immunological checkpoint in cancer cells. The binding of PD-L1 and PD-1 promotes T-cell tolerance and helps tumor cells escape from host immunity. Immunotherapy targeting the PD-L1/PD-1 axis has been developed as an anti-cancer therapy and used in treating advanced human non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Yes-associated protein (YAP) is a key mediator of the Hippo/YAP signaling pathway, and plays important roles in promoting cancer development, drug resistance and metastasis in human NSCLC and MPM. YAP has been suggested as a new therapeutic target in NSCLC and MPM. The role of YAP in regulating tumor immunity such as PD-L1 expression has just begun to be explored, and the correlation between YAP-induced tumorigenesis and host anti-tumor immune responses is not well known. Here, we review recent studies investigating the correlation between YAP and PD-L1 and demonstrating the mechanism by which YAP regulates PD-L1 expression in human NSCLC and MPM. Future work should focus on the interactions between Hippo/YAP signaling pathways and the immune checkpoint PD-L1/PD-1 pathway. The development of new synergistic drugs for immune checkpoint PD-L1/PD-1 blockade in NSCLC and MPM is warranted. View Full-Text
Keywords: yes-associated protein (YAP); programmed death-ligand 1 (PD-L1); non-small cell lung cancer (NSCLC); malignant pleural mesothelioma (MPM); immunotherapy yes-associated protein (YAP); programmed death-ligand 1 (PD-L1); non-small cell lung cancer (NSCLC); malignant pleural mesothelioma (MPM); immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Hsu, P.-C.; Yang, C.-T.; Jablons, D.M.; You, L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines 2018, 6, 114. https://doi.org/10.3390/biomedicines6040114

AMA Style

Hsu P-C, Yang C-T, Jablons DM, You L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines. 2018; 6(4):114. https://doi.org/10.3390/biomedicines6040114

Chicago/Turabian Style

Hsu, Ping-Chih; Yang, Cheng-Ta; Jablons, David M.; You, Liang. 2018. "The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer" Biomedicines 6, no. 4: 114. https://doi.org/10.3390/biomedicines6040114

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop